MONEPANTEL: Safety Summary for Veterinary Use
WHO Acute Hazard classification: Not listed.
The molecular mode of action of monepantel is different to the one of all other anthelmintics. Monepantel acts on a particular nicotinic acetylcholine receptor subunit (Hco-MPTL-1) that occurs only in nematodes and not in other organisms, e.g. in mammals. As all other acetylcholine receptors, this particular one is also present in the membrane of certain neurons and neuromuscular junctions and is responsible for the correct transmission of the nerve signals. Monepantel blocks these receptors and the affected worms are paralyzed and die or are expelled.
- LD50 acute, rats, p.o. >2000 mg/kg
- LD50 acute, rats, dermal >2000 mg/kg
- Sheep and goats tolerate monepantel very well.
- Adult sheep tolerate single oral doses of up to 125 mg/kg (~33x the therapeutic dose) without toxic symptoms.
- Lambs 2 to 4 weeks old tolerated doses of up to 37.5 mg/kg (10x the therapeutic dose) without toxic symptoms. Lambs 12 to 15 weeks old tolerated repeated treatment at 18.5 mg/kg (5x the recommended dose) every 3 weeks, during 24 weeks (8 treatments) without toxic symptoms.
- As a general rule, poisoning with monepantel is quite unusual, due to its low toxicity, the high safety margins and the fact that most sheep and goats tolerate monepantel very well.
- In safety studies in dogs and rats the most affected organ after heavy overdosing was the liver. Increased weights of the thymus, thyroid and adrenal glands were also recorded.
- In most tolerance studies no external symptoms of toxicity were observed. Following treatment at 125 mg/kg (33x the recommended dose) transient decrease of appetite, slight increases in several plasma values (fluoride oxalate glucose, serum glucose, urea, alanine aminotransferase) and slight decrease of hemoglobin.
- No adverse drug reactions have been recorded after treatment at the recommended dose.
- There is no specific antidote for monepantel.
- Treatment consists in supportive and symptomatic measures.
- After oral administration monepantel is quickly absorbed into the bloodstream and rapidly metabolized to monepantel's sulfone derivative that has a similar efficacy as the parent molecule. Four hours after administration, the sulfone derivative predominates over the parent molecule. Mean residence time in blood for monepantel and monepantel sulfone are about 5 and 110 hours, respectively.
- About 95% of the administered dose is metabolized to the sulfone derivative. The maximum blood concentration of the sulfone derivative is reached about 2 hours after administration.
- Only about 4% of the administered dose is excreted unchanged through the feces. About 27% of the administered dose is excreted through the feces in the form of the sulfone derivative. The remaining amount is further metabolized and partly excreted through urine (up to 30% of the administered dose).
- Monepantel is slightly toxic to fish and aquatic invertebrates (>100 mcg/l).
- Not being used in crop pesticides or in public hygiene, knowledge on its environmental fate and impact is very scarce.
- Nevertheless, it can be assumed that correctly used in sheep and goats, monepantel is unlikely to be detrimental for the environment, including coprophagous insects.
Click here for a list and overview of all safety summaries of antiparasitic active ingredients in this site.
- Monepantel belongs to the chemical class of the amino-acetonitrile derivatives.
- Monepantel is not used in human medicines.
- Monepantel is not used in crop pesticides.
- Monepantel is not used in public or domestic hygiene as a biocide.
- Click here for General safety of antiparasitics for domestic animals.
- Click here for General safety of antiparasitics for humans.
- Click here for General safety of antiparasitics for the environment.
- Click here for technical and commercial information on monepantel.
If you intend to use a veterinary drug containing this active ingredient you must carefully read and follow the safety instructions in the product label. Always ask your veterinary doctor, or pharmacist, or contact the manufacturer. Be aware that the safety instructions for the same veterinary medicine may vary from country to country.
The information in this page must not be confused with the Materials and Safety Datasheets (MSDS) officially issued by manufacturers for active ingredients and many other chemicals. MSDSs target safety during manufacturing, transport, storage and handling of such materials. This safety summary is a complement to the information on product labels and MSDS.
The toxicity of an active ingredient must not be confused with the toxicity of finished products, in this case parasiticidal drugs or pesticides. Finished products contain one or more active ingredients, but also other ingredients that can be relevant from the safety point of view.
All information in this site is made available in good faith and following a reasonable effort to ensure its correctness and actuality. Nevertheless, no this regarding guarantee is given, and any liability on its accuracy, integrity, sufficiency, actuality and opportunity is denied. Liability is also denied for any possible damage or harm to persons, animals or any other goods that could follow the transmission or use of the information, data or recommendations in this site by any site visitor or third parties.